SAB BIOTHERAPEUTICS, INC. Finance Lease, Liability, Undiscounted Excess Amount
SAB BIOTHERAPEUTICS, INC. (SABS) had Finance Lease, Liability, Undiscounted Excess Amount of $1.78 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount · last filed 2026-08-06
- 2026-06-30: Finance Lease, Liability, Undiscounted Excess Amount $1.78M.
- 2026-03-31: Finance Lease, Liability, Undiscounted Excess Amount $1.85M.
- 2025-12-31: Finance Lease, Liability, Undiscounted Excess Amount $1.91M.
- 2025-09-30: Finance Lease, Liability, Undiscounted Excess Amount $1.97M.
| Period end | Finance Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2026-06-30 | $1.78M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $1.85M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $1.91M 10-K · filed 2026-03-09 |
| 2025-09-30 | $1.97M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $2.04M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $2.10M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $2.17M 10-K · filed 2025-03-31 |
| 2024-09-30 | $2.24M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $2.30M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $2.37M 10-Q · filed 2024-05-20 |
| 2023-12-31 | $2.44M 10-K · filed 2024-03-29 |
| 2023-09-30 | $2.51M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $2.58M 10-Q · filed 2023-08-21 |
| 2023-03-31 | $2.56M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $2.63M 10-K · filed 2023-04-14 |
| 2022-09-30 | $2.70M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $2.77M 10-Q · filed 2022-08-10 |
| 2022-03-31 | $2.84M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $2.92M 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |